# STC2 promotes anoikis resistance by modulating TGIF1 mRNA stability in colorectal cancer

## TL;DR

STC2 helps colorectal cancer cells survive detachment by stabilizing TGIF1 mRNA, making it a potential treatment target.

## Contribution

STC2's role in CRC is revealed through its stabilization of TGIF1 mRNA, a novel mechanism for anoikis resistance.

## Key findings

- STC2 is upregulated in CRC tissues and linked to poor patient outcomes.
- STC2 enhances CRC cell survival by stabilizing TGIF1 mRNA.
- STC2 binds to and inhibits degradation of TGIF1 mRNA.

## Abstract

Stanniocalcin-2 (STC2), a glycosylated protein originally identified in the endocrine glands of fish, plays multiple biological roles in cancer. However, its functional significance and molecular mechanisms in colorectal cancer (CRC) remain unclear.

Bioinformatic analyses and CRC tissue specimens were used to determine STC2 expression and its prognostic value. The biological effects of STC2 on CRC cells were assessed using flow cytometry and live/dead staining assays. The underlying mechanisms were further explored by RNA sequencing, RNA immunoprecipitation (RIP), and RNA stability assays.

STC2 was significantly upregulated in CRC tissues and cell lines, and its high expression was associated with poor prognosis in CRC patients. Functional experiments demonstrated that STC2 enhanced CRC cell resistance to anoikis by upregulating TGIF1 expression. Mechanistically, STC2 bound to TGIF1 mRNA and stabilized it by inhibiting its degradation.

Our findings suggest that STC2 promotes anoikis resistance in CRC by regulating TGIF1 mRNA stability. STC2 may serve as a potential therapeutic target and prognostic biomarker for colorectal cancer.